Open AccessLong-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies
Author(s) -
Roger H. Kobayashi,
Jiří Litzman,
Isaac Melamed,
J. Fernando Mandujano,
Ai Kobayashi,
Bruce Ritchie,
Bob Geng,
T. Prescott Atkinson,
Syed Shakil Ur Rehman,
Sonja Höller,
Eva Turpel-Kantor,
Huub T. C. Kreuwel,
J C Speer,
Sudhir Gupta
Publication year - 2022
Publication title -
clinical and experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1093/cei/uxac092
Subject(s) - tolerability , medicine , adverse effect , prospective cohort study , incidence (geometry) , clinical endpoint , clinical trial , physics , optics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom